Besides preventive measures that are available for patients who test positive for a BRCA1/2 gene mutation and have increased risk to develop a second primary breast cancer and ovarian cancer [36–38], GCT also provides information for the family members of tested individuals. This evidence concerns the gene BRCA1 and breast cancer.